Navigation Links
Metabolex Announces Election of Kurt von Emster to Board of Directors
Date:4/22/2009

HAYWARD, Calif., April 22 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new therapeutics for the treatment of diabetes and related metabolic disorders, announced that Kurt von Emster has been elected to its Board of Directors.

Mr. von Emster currently serves as a Managing Director of venBio. From November 2000 to March 2009, Mr. von Emster was Managing Director of MPM BioEquities and a Portfolio Manager for the MPM BioEquities Fund. From July 1989 to November 2000, Mr. von Emster was with the Franklin Templeton Group, most recently as a Vice President and Portfolio Manager. Mr. von Emster is currently a member of the board of directors at Somaxon Pharmaceuticals, Inc., and Facet Biotech, both public biotechnology companies. Mr. von Emster is a Chartered Financial Analyst (CFA), a member of the Association for Investment Management and Research and of the Security Analysts of San Francisco. Mr. von Emster received his B.S. degree from the University of California at Santa Barbara.

"Mr. von Emster brings to the Board the perspective of a seasoned private and public company investor," said Harold Van Wart, Ph.D., president and chief executive officer of Metabolex. "We look forward to his input and expertise as the company continues to build upon its recent clinical successes." Mr. von Emster's appointment follows the resignation of Rob Chess from the Board of Directors. Dr. Van Wart added, "I would like to thank Rob for his many valuable contributions to Metabolex during his Board tenure."

About Metabolex

Metabolex is a privately-held biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, with an emphasis on type 2 diabetes. Metabolex has drawn on its deep understanding of diabetes to create a large database of genes in
'/>"/>

SOURCE Metabolex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Metabolex Announces Positive Results From Phase 1a Clinical Trial of MBX-2982
2. Two Metabolex Projects Recognized in Windhovers Top 10 Lists for Partnering Opportunities
3. Metabolex Names Zhao, Martin to Executive Posts
4. Metabolex Appoints Donald Hill as Chief Financial Officer
5. Yongye Biotechnology Announces Preliminary Results for its Fiscal Quarter Ended March 31, 2009
6. HUYA Bioscience Announces Strategic Alliance With Abbott on Drug and Biomarker Development Candidates From China
7. Bio-Matrix Scientific Group, Inc. Announces Preferred Stock Dividend and Spinoff of Wholly-Owned Subsidiary, Entest Biomedical, Inc.
8. Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models
9. E&K Scientific Announces New Accuflow Product Line
10. Thoratec Announces Filing of PMA Seeking Destination Therapy Approval for HeartMate II(R)
11. International Society for Medical Publication Professionals (ISMPP) Announces First CMPP Exam Window Closes, Next Opportunity in September
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... new research platform uses a laser to ... undergoing stress and heating, an approach likely ... microelectronics and batteries., This new technique, called ... heating and the surface stress of microscale ... discussed the merits of surface-stress influence on ...
(Date:8/28/2014)... 2014  Next month, executives from clinical trial marketing firm ... beginning with Patient-Centered Clinical Trials 2014 , to be ... , September 4-5. Patient recruitment experts Bonnie A. ... will share insights on the benefits of employing an ... – from media to mobile apps – can be used ...
(Date:8/28/2014)... by a Florida State University research team has led ... temperature, emit white light, and convert photon energy directly ... a butterfly. , Biwu Ma, associate professor in the ... College of Engineering, created the molecule in a lab ... that his creation has many other unique capabilities. , ...
(Date:8/28/2014)... PrimeSource Building Products, Inc., a leading ... to support their communication needs with the ... conferencing platform GlobalMeet powered by SoundConnect. The solution ... SoundConnect delivers award winning “results driven” business class ... be utilizing GlobalMeet powered by SoundConnect ...
Breaking Biology Technology:New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3BBK Worldwide Leads Sessions at Key September Events 2Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2PrimeSource Chooses SoundConnect as Collaboration Provider 2
... tiny components on silicon wafers) has long enabled the ... number of transistors that can be squeezed into an ... compensating capabilities of plasma etching, Moore,s Law would have ... micron (the diameter of a human hair is approximately ...
... 2011 Bayer HealthCare,s affiliate MEDRAD, Inc. today ... demonstrated a 59 percent relative reduction in target ... patients with peripheral arterial disease (PAD) treated with ... compared to standard balloon angioplasty (POBA). Additionally, for ...
... /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. ... outsourcing company serving the pharmaceutical, biotechnology, and medical device industries, ... its financial results for the third quarter of 2011. ... Increased 24.0% Year Over Year to $104.0 Million ...
Cached Biology Technology:Plasma etching pushes the limits of a shrinking world 2Bayer HealthCare's Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon 2Bayer HealthCare's Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon 3Bayer HealthCare's Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon 4WuXi PharmaTech Announces Third-Quarter 2011 Results 2WuXi PharmaTech Announces Third-Quarter 2011 Results 3WuXi PharmaTech Announces Third-Quarter 2011 Results 4WuXi PharmaTech Announces Third-Quarter 2011 Results 5WuXi PharmaTech Announces Third-Quarter 2011 Results 6WuXi PharmaTech Announces Third-Quarter 2011 Results 7WuXi PharmaTech Announces Third-Quarter 2011 Results 8WuXi PharmaTech Announces Third-Quarter 2011 Results 9WuXi PharmaTech Announces Third-Quarter 2011 Results 10WuXi PharmaTech Announces Third-Quarter 2011 Results 11WuXi PharmaTech Announces Third-Quarter 2011 Results 12WuXi PharmaTech Announces Third-Quarter 2011 Results 13WuXi PharmaTech Announces Third-Quarter 2011 Results 14WuXi PharmaTech Announces Third-Quarter 2011 Results 15WuXi PharmaTech Announces Third-Quarter 2011 Results 16WuXi PharmaTech Announces Third-Quarter 2011 Results 17WuXi PharmaTech Announces Third-Quarter 2011 Results 18
(Date:8/29/2014)... connections in transcription factor networks (TFNs) to evaluate the ... in PLOS Computational Biology in August. ... a network,s resilience against mutations. , "In simulations, ... models has a greater effect on robustness than varying ... Dov A. Pechenick, PhD, lead author and former researcher ...
(Date:8/29/2014)... twist them, fold them: modern materials that are light, ... as artificial skin or electronic paper. , Making such ... but a new way of working with copper nanowires ... , Previous success in the field of ultra-lightweight ... precious gold and silver nanowires. , By turning ...
(Date:8/28/2014)... study reports that an expansion of marine protected areas ... ecological functions. According to investigators from the Wildlife ... fish have focused on saving the largest numbers of ... provide key and difficult-to-replace ecological functions. , ... by fish species that also are food for millions ...
Breaking Biology News(10 mins):Assortativity signatures of transcription factor networks contribute to robustness 2Copper shines as flexible conductor 2Study finds marine protected areas inadequate for protecting fish and ocean ecology 2
... Infectious Diseases (NIAID), part of the National Institutes of ... to Tulane University for its ongoing efforts to treat ... that threatens hundreds of thousands of people annually in ... threat. The contract will include collaboration between Tulane; ...
... are going on a diet, while others have expanding ... rising temperatures due to global climate change, speculates Prof. ... who has been measuring the evolving body sizes of ... most extreme. , Changes are happening primarily in higher ...
... (February 5, 2010) New research from the Hood Center for ... first time sheds light on the significant potential negative impact ... on children. The study, which appears in the current ... of the "brand placements" for food, beverage, and food retail ...
Cached Biology News:Tulane receives $15 million NIH contract to develop vaccine and treatment for deadly fever 2Animals cope with climate change at the dinner table 2New study examines the impact on children of food product placements in the movies 2New study examines the impact on children of food product placements in the movies 3
Each 72-well MiniTray is low profile, with lid. Conical well shape, 10 l....
The E. coli Expression System with Gateway Technology is designed to create E. coli expression clones containing the T7 promoter. The expression clones are ready for transformation and expression in ...
...
For use with SSP products or any application requiring agarose gel separation • Multiple formats available to meet various throughput needs • Includes replacement parts for each un...
Biology Products: